Upon intestinal infection with Clostridium difficile (CDI), the major unmet clinical need is the high rate of recurrent infections (25-65%) that often become chronic, resulting in costly hospital reimbursement penalties and repeated medical treatment of the patient.
Proxi Biotech’s solution, ReCloSure, is an active immunotherapy helping patients and healthcare systems escape recurrent CDI and offering an effective alternative to fecal microbiome transplantation.
Proxi Biotech has a full preclinical package on ReCloSure demonstrating, stability, superior immunity, excellent safety in a GLP-certified toxicology study and 100% efficacy. Currently, we are preparing a clinical trial application to the regulatory authorities in Australia and are looking for support to conduct a phase I trial in 2026.